{"id":33918,"date":"2020-08-28T15:54:30","date_gmt":"2020-08-28T14:54:30","guid":{"rendered":"https:\/\/www.biotechpharmasummit.com\/?page_id=33918"},"modified":"2021-03-19T10:30:13","modified_gmt":"2021-03-19T10:30:13","slug":"liquid-biopsy-2020-speakers","status":"publish","type":"page","link":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/","title":{"rendered":"Liquid Biopsy 2020 Speakers"},"content":{"rendered":"
\n

\n\tOur
Speakers (A-Z)
\n\t<\/h2>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Akoulitchev_Liquid_Biopsy_2020_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Akoulitchev_Liquid_Biopsy_2020_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Akoulitchev_Liquid_Biopsy_2020_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Akoulitchev_Liquid_Biopsy_2020_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Akoulitchev_Liquid_Biopsy_2020_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Akoulitchev_Liquid_Biopsy_2020_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Akoulitchev_Liquid_Biopsy_2020_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”34006″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/alexandre-akoulitchev\/akoulitchev_liquid_biopsy_2020_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Akoulitchev_Liquid_Biopsy_2020_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"4.5","credit":"","camera":"","caption":"","created_timestamp":"1313675012","copyright":"COPYRIGHT, 2006","focal_length":"19.8","iso":"200","shutter_speed":"0.022222222222222","title":"","orientation":"1"}” data-image-title=”Akoulitchev_Liquid_Biopsy_2020_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Akoulitchev_Liquid_Biopsy_2020_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Akoulitchev_Liquid_Biopsy_2020_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAlexandre Akoulitchev\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chief Scientific Officer at Oxford BioDynamics Plc<\/h5>\n

\n\t\t\t\n\t3D Genome Architecture as Biomarker Modality\n\t\t\t<\/a>\n\t<\/h3>\n\t

Alexandre read mathematics, physics, chemistry, biochemistry and biophysics at Moscow Institute of Physics and Technology.  In 1989 he was selected by the George Soros Foundation for the Oxford Scholarships, associated with St. Antony\u2019s College, Oxford. He obtained his PhD in cell biology from University College, London, with the research based at the Imperial Cancer Research Fund Laboratories.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Anders-Sta\u030ahlberg_University_Photo-1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Anders-Sta\u030ahlberg_University_Photo-1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Anders-Sta\u030ahlberg_University_Photo-1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Anders-Sta\u030ahlberg_University_Photo-1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Anders-Sta\u030ahlberg_University_Photo-1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Anders-Sta\u030ahlberg_University_Photo-1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Anders-Sta\u030ahlberg_University_Photo-1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”34021″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/anders-stahlberg\/anders-sta%cc%8ahlberg_university_photo-2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Anders-Sta\u030ahlberg_University_Photo-1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2","credit":"","camera":"Canon EOS 600D","caption":"","created_timestamp":"1361803640","copyright":"","focal_length":"50","iso":"100","shutter_speed":"0.00625","title":"","orientation":"1"}” data-image-title=”Anders-Sta\u030ahlberg_University_Photo” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Anders-Sta\u030ahlberg_University_Photo-1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Anders-Sta\u030ahlberg_University_Photo-1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tAnders St\u00e5hlberg\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Principal investigator at University of Gothenburg \/ Sahlgrenska University Hospital<\/h5>\n

\n\t\t\t\n\tTechnical and biological challenges when analyzing cell-free tumor DNA\n\t\t\t<\/a>\n\t<\/h3>\n\t

Anders St\u00e5hlberg is working as principal investigator at the Sahlgrenska Cancer Center, University of Gothenburg and Sahlgrenska University Hospital in Sweden. He has a PhD in molecular biotechnology and has two post-doc periods working with human embryonic stem cells and tumor biology. Anders primary research interest is to understand molecular mechanisms in tumor initiation and tumor development, focusing on breast cancer and sarcomas.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Arjan_Tibbe_VyCAP_Photo_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Arjan_Tibbe_VyCAP_Photo_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Arjan_Tibbe_VyCAP_Photo_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Arjan_Tibbe_VyCAP_Photo_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Arjan_Tibbe_VyCAP_Photo_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Arjan_Tibbe_VyCAP_Photo_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Arjan_Tibbe_VyCAP_Photo_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”34011″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/arjan-tibbe\/arjan_tibbe_vycap_photo_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Arjan_Tibbe_VyCAP_Photo_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Arjan_Tibbe_VyCAP_Photo_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Arjan_Tibbe_VyCAP_Photo_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Arjan_Tibbe_VyCAP_Photo_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tArjan Tibbe\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CEO at VyCAP<\/h5>\n

\n\t\t\t\n\tFrom liquid biopsy to single cell data\n\t\t\t<\/a>\n\t<\/h3>\n\t

The past 20 years Arjan Tibbe worked on the cutting edge between the medical technology and applied physics. He combined the principles of physics with the medical needs.<\/p>\n

After completing his PhD in 2001 he established and managed Immunicon Europe, Enschede, the Netherlands, a subsidiary of Immunicon Corporation, USA. Immunicon developed the FDA cleared CellSearch system for monitoring metastatic cancer by measuring the number of CTC.<\/p>\n\t\t\t\t\t\t\t\"\"\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33959″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/catherine-alix-panabieres\/catherine_alix-panabieres_liquid_biopsy_2020_lisbon_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"11","credit":"","camera":"Canon EOS 5D Mark II","caption":"","created_timestamp":"1510052720","copyright":"","focal_length":"45","iso":"200","shutter_speed":"0.005","title":"","orientation":"1"}” data-image-title=”Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Catherine_Alix-Panabieres_Liquid_Biopsy_2020_Lisbon_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tCatherine Alix-Panabi\u00e8res\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Director LCCRH at the University Medical Center of Montpellier<\/h5>\n

\n\t\t\t\n\tCirculating Tumor Cells: Finding Rare Events for a Huge Knowledge of Cancer Dissemination\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Catherine Alix-Panabi\u00e8res received her PhD degree in 1998 at the Institute of Virology, University Louis Pasteur, in Strasbourg in France and in 1999, she moved to Montpellier where she did a postdoctoral research at the University Medical Centre. During this last decade, Dr Alix-Panabi\u00e8res has focused on optimizing new techniques of enrichment, detection and characterization of viable circulating tumor cells (CTCs) in patients with solid tumors.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christian_Werno_Fraunhofer_Institute_Photo_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christian_Werno_Fraunhofer_Institute_Photo_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christian_Werno_Fraunhofer_Institute_Photo_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christian_Werno_Fraunhofer_Institute_Photo_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christian_Werno_Fraunhofer_Institute_Photo_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christian_Werno_Fraunhofer_Institute_Photo_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christian_Werno_Fraunhofer_Institute_Photo_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”34000″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/christian-werno\/christian_werno_fraunhofer_institute_photo_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christian_Werno_Fraunhofer_Institute_Photo_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"Patrick Reinig","camera":"","caption":"","created_timestamp":"1561377309","copyright":"www.patrick-reinig.com","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Christian_Werno_Fraunhofer_Institute_Photo_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christian_Werno_Fraunhofer_Institute_Photo_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Christian_Werno_Fraunhofer_Institute_Photo_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tChristian Werno\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Research group leader at Fraunhofer Institute<\/h5>\n

\n\t\t\t\n\tClinical integration of liquid biopsy\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. rer. med. Christian Werno is research group leader \u201cPreclinical Therapy Models\u201d, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Division of Personalized Tumor Therapy.<\/p>\n

He got his PhD at Goethe University Frankfurt am Main, then being a postdoctoral fellow at Fraunhofer ITEM Regensburg Division of Personalized Tumor Therapy.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Clotilde_Costa_Roche-Chus_Photo_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Clotilde_Costa_Roche-Chus_Photo_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Clotilde_Costa_Roche-Chus_Photo_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Clotilde_Costa_Roche-Chus_Photo_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Clotilde_Costa_Roche-Chus_Photo_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Clotilde_Costa_Roche-Chus_Photo_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Clotilde_Costa_Roche-Chus_Photo_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33929″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/clotilde-costa-nogueira\/clotilde_costa_roche-chus_photo_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Clotilde_Costa_Roche-Chus_Photo_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.8","credit":"","camera":"Canon EOS-1D X","caption":"","created_timestamp":"1507630287","copyright":"","focal_length":"93","iso":"5000","shutter_speed":"0.00125","title":"","orientation":"1"}” data-image-title=”Clotilde_Costa_Roche-Chus_Photo_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Clotilde_Costa_Roche-Chus_Photo_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Clotilde_Costa_Roche-Chus_Photo_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tClotilde Costa Nogueira\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Leader of the Liquid Biopsy Line at the Joint Unit Roche-Chus<\/h5>\n

\n\t\t\t\n\tCTCs characterization for metastatic breast cancer patients follow-up\n\t\t\t<\/a>\n\t<\/h3>\n\t

Clotilde Costa Nogueira is a Biologist. In 2011 Clotilde Costa Nogueira developed her phD in Molecular Oncology at CIEMAT (Madrid) focused on the study of cell cycle genes in squamous cell carcinomas.<\/p>\n

In 2013 she moved to Santiago de Compostela to the Translational Medical Oncology Group to work in the study of metastasis through Liquid Biopsy.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Daniel_Gro\u0308lz_QIAGEN_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Daniel_Gro\u0308lz_QIAGEN_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Daniel_Gro\u0308lz_QIAGEN_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Daniel_Gro\u0308lz_QIAGEN_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Daniel_Gro\u0308lz_QIAGEN_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Daniel_Gro\u0308lz_QIAGEN_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Daniel_Gro\u0308lz_QIAGEN_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33981″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/daniel-grolz\/daniel_gro%cc%88lz_qiagen_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Daniel_Gro\u0308lz_QIAGEN_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"3.5","credit":"","camera":"Canon PowerShot G12","caption":"","created_timestamp":"1341344154","copyright":"","focal_length":"13.761","iso":"400","shutter_speed":"0.00625","title":"","orientation":"1"}” data-image-title=”Daniel_Gro\u0308lz_QIAGEN_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Daniel_Gro\u0308lz_QIAGEN_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Daniel_Gro\u0308lz_QIAGEN_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tDaniel Gr\u00f6lz\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Scientific Associate Director R&D, Sample Technologies Department at QIAGEN<\/h5>\n

\n\t\t\t\n\tCirculating tumor DNA- preanalytical considerations, international specimen improvement requirements, standards, legislation, technologies\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Daniel Gr\u00f6lz is a Scientific Associate Director of Research and Development at QIAGEN in Hilden, Germany. Dr. Groelz is the R&D project manager who led an international team within PreAnalytiX GmbH to develop the PAXgene Tissue and the PAXgene Blood ccfDNA Systems.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33964″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/davide-zocco\/davide_zocco_exosomics_photo_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"Bruno Bruchi Photonbrunobruchi@gmail.comnwww.brunobruchi.it","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”davide_zocco_exosomics_Photo_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/davide_zocco_exosomics_Photo_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tDavide Zocco\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Head of R&D at Exosomics<\/h5>\n

\n\t\t\t\n\tExtracellular vesicles (EVs)\n\t\t\t<\/a>\n\t<\/h3>\n\t

Davide Zocco joined Exosomics in 2013 with the mandate to introduce and implement into the R&D pipeline the development of molecular assays for detection of EV shuttled mutations.<\/p>\n

In 2015 he took on the role of the Head of Molecular Diagnostics. Today he is responsible for development of EV-DNA and EV-RNA targeted solutions and for management of clinical testing of assay prototypes.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fabrice_Magnino_Illumina_Liquid_Biopsy_Lisbon_1.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fabrice_Magnino_Illumina_Liquid_Biopsy_Lisbon_1-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fabrice_Magnino_Illumina_Liquid_Biopsy_Lisbon_1-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fabrice_Magnino_Illumina_Liquid_Biopsy_Lisbon_1-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fabrice_Magnino_Illumina_Liquid_Biopsy_Lisbon_1-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fabrice_Magnino_Illumina_Liquid_Biopsy_Lisbon_1-420×627.png 420w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33987″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/fabrice-magnino\/fabrice_magnino_illumina_liquid_biopsy_lisbon_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fabrice_Magnino_Illumina_Liquid_Biopsy_Lisbon_1.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Fabrice_Magnino_Illumina_Liquid_Biopsy_Lisbon_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fabrice_Magnino_Illumina_Liquid_Biopsy_Lisbon_1-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Fabrice_Magnino_Illumina_Liquid_Biopsy_Lisbon_1-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tFabrice Magnino\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Assoc Director, Medical Affairs EMEA at illumina<\/h5>\n

\n\t\t\t\n\tLiquid Biopsy and Tumour Comprehensive Genomic Profiling – Future Standard of Care?\n\t\t\t<\/a>\n\t<\/h3>\n\t

Fabrice Magnino is holding a PhD in Tumour Biology from the Medical Faculty of Berne (Switzerland) and received Breast Cancer postdoctoral training at the Cancer Institute of Montpellier (France) before joining the Life Science and Molecular Diagnostic industry where he is focusing on solutions to improve patient management.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33050″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/biobanking-2019-speakers\/jens-k-habermann\/jens_habermann_esbb_biotech_pharma_summit_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"8","credit":"","camera":"Canon EOS 60D","caption":"","created_timestamp":"1439462938","copyright":"","focal_length":"85","iso":"125","shutter_speed":"0.00625","title":"","orientation":"1"}” data-image-title=”Jens_Habermann_ESBB_BioTech_Pharma_Summit_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Jens_Habermann_ESBB_BioTech_Pharma_Summit_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJens K. Habermann\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
President of ESBB<\/h5>\n

\n\t\t\t\n\tStandardized preprocessing of liquid biopsies through biobanks enables precision medicine\n\t\t\t<\/a>\n\t<\/h3>\n\t

Professor Jens K. Habermann, m.d., Ph.D., is director of ICB-L (Interdisciplinary Center for Biobanking-L\u00fcbeck) and scientific director of UCCL (University Cancer Center L\u00fcbeck) at the University of L\u00fcbeck and University Clinic Schleswig-Holstein. He obtained his Ph.D. at the Karolinska Institutet (Stockholm, Sweden) and postdoc training at the NCI, NIH (Bethesda, USA).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33937″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/juan-f-roman\/juan_roman_ximedica_liquid_biopsy_lisbon_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Juan_Roman_ximedica_Liquid_Biopsy_Lisbon_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tJuan F. Roman\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
VP Business Development at ximedica<\/h5>\n

\n\t\t\t\n\tChallenges to the adoption of Liquid Biopsy\n\t\t\t<\/a>\n\t<\/h3>\n\t

Juan F. Roman is a Medical technology business developer with an international world-class technical and commercial background. A career of over twenty years in Diagnostics and MedTech, always working in forefront technologies, with the most recent ten years successfully involved in the organisation of research and development joint ventures with blue-chip healthcare, diagnostics and life sciences companies.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pantel_Klaus_Liquid_Biopsy_2020_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pantel_Klaus_Liquid_Biopsy_2020_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pantel_Klaus_Liquid_Biopsy_2020_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pantel_Klaus_Liquid_Biopsy_2020_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pantel_Klaus_Liquid_Biopsy_2020_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pantel_Klaus_Liquid_Biopsy_2020_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pantel_Klaus_Liquid_Biopsy_2020_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33924″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/klaus-pantel\/pantel_klaus_liquid_biopsy_2020_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pantel_Klaus_Liquid_Biopsy_2020_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"7.1","credit":"Eva Hecht","camera":"Canon EOS 5D Mark III","caption":"v1; Portrait; Portru00e4t; Prof. Dr. med. Klaus Pantel; Institutsdirektor; Zentrum fu00fcr Experimentelle Medizin; Institut fu00fcr Tumorbiologie","created_timestamp":"1575373104","copyright":"UKE Unternehmenskommunikation, Bereich Foto\/Grafik Hamburg","focal_length":"85","iso":"200","shutter_speed":"0.008","title":"","orientation":"1"}” data-image-title=”Pantel_Klaus_Liquid_Biopsy_2020_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pantel_Klaus_Liquid_Biopsy_2020_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Pantel_Klaus_Liquid_Biopsy_2020_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tKlaus Pantel\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf<\/h5>\n

\n\t\t\t\n\tLiquid Biopsies: From Discovery to Clinical Implementation\n\t\t\t<\/a>\n\t<\/h3>\n\t

Prof Klaus Pantel is Chairman of the Institute of Tumour Biology at the University Medical Center Hamburg-Eppendorf. The institute is part of the Centre of Experimental Medicine and the University Cancer Center Hamburg (UCCH). Prof Pantel graduated in 1986 from Cologne University in Germany and completed his thesis on mathematical modelling of haematopoiesis in 1987. After his postdoctoral period in the USA on hematopoietic stem cell regulation (Wayne State University, Detroit), he performed research at the Institute of Immunology, University of Munich for 10 years.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorena_Dieguez_INL_Photo_2.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorena_Dieguez_INL_Photo_2-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorena_Dieguez_INL_Photo_2-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorena_Dieguez_INL_Photo_2-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorena_Dieguez_INL_Photo_2-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorena_Dieguez_INL_Photo_2-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorena_Dieguez_INL_Photo_2-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33976″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/lorena-dieguez\/lorena_dieguez_inl_photo_2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorena_Dieguez_INL_Photo_2.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"2.2","credit":"","camera":"ILCE-7","caption":"","created_timestamp":"1551110418","copyright":"","focal_length":"50","iso":"400","shutter_speed":"0.00625","title":"","orientation":"1"}” data-image-title=”Lorena_Dieguez_INL_Photo_2″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorena_Dieguez_INL_Photo_2-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Lorena_Dieguez_INL_Photo_2-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tLorena Di\u00e9guez\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Group Leader Medical Devices at INL \u2013 International Iberian Nanotechnology Laboratory<\/h5>\n

\n\t\t\t\n\tNew platforms from CTC isolation and analysis.\n\t\t\t<\/a>\n\t<\/h3>\n\t

Lorena Di\u00e9guez joined INL in 2014 as Staff Researcher and is, since May 2018, the leader of the Medical Devices research group. Her research is focused in the development of biomicrofluidic devices mainly devoted to Translational Medical Research in close collaboration with Hospitals. For that purpose, her work is devoted to the development of integrated biosensing systems and nanobioengineered diagnostics microsystems for the isolation and characterization of Tumor Cells from body fluids of cancer patients, as well as the development of microfluidic organ-on-a-chip 3D models.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marianne_Oulhen_Liquid_Biopsy_2020_1.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marianne_Oulhen_Liquid_Biopsy_2020_1-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marianne_Oulhen_Liquid_Biopsy_2020_1-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marianne_Oulhen_Liquid_Biopsy_2020_1-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marianne_Oulhen_Liquid_Biopsy_2020_1-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marianne_Oulhen_Liquid_Biopsy_2020_1-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marianne_Oulhen_Liquid_Biopsy_2020_1-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33994″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/marianne-oulhen\/marianne_oulhen_liquid_biopsy_2020_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marianne_Oulhen_Liquid_Biopsy_2020_1.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Marianne_Oulhen_Liquid_Biopsy_2020_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marianne_Oulhen_Liquid_Biopsy_2020_1-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Marianne_Oulhen_Liquid_Biopsy_2020_1-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMarianne Oulhen\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Project Manager at Gustave Roussy<\/h5>\n

\n\t\t\t\n\tCirculating Tumor Cells in Monitoring Cancer\n\t\t\t<\/a>\n\t<\/h3>\n\t

Marianne Oulhen is a research engineer at Gustave Roussy . She works in the Dr Fran\u00e7oise Farace\u2019s team in the Translational Laboratory of Rare Circulating Cells (CNRS UMS3655 \u2013 INSERM US23 AMMICA) and the Circulating Tumor Cells team at INSERM U981. She has a \u201cbiotechnologies and Biohealth\u201d master\u2019s degree. For the past ten years, she focused her research on circulating tumor cells with the goal of identifying both sensitivity and resistance biomarkers of anticancer therapies.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2.jpeg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-201×300.jpeg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-768×1146.jpeg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-630×940.jpeg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-420×627.jpeg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-315×470.jpeg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”32555″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/companion-diagnostics-biomarkers-2017-speakers\/martina-kaufmann\/martina-kaufmann-2\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2.jpeg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"6.3","credit":"liegen bei der Bildautorin","camera":"NIKON D3X","caption":"Martina Kaufmann;nDu00f6bele Design – Wiesbaden","created_timestamp":"1348580020","copyright":"www.katrindenkewitz.de","focal_length":"105","iso":"200","shutter_speed":"0.00625","title":"Martina Kaufmann","orientation":"1"}” data-image-title=”Martina Kaufmann” data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-201×300.jpeg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/07\/Martina_Kaufmann_Consulting_BioTech_Pharma_Summit_Profile_2-686×1024.jpeg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMartina Kaufmann\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Managing Director at Martina Kaufmann Strategic Consulting<\/h5>\n

\n\t\t\t\n\tLiquid Biopsies: Coming of age processing tools\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Martina Kaufmann, Managing Director at Martina Kaufmann Strategic Consulting (www.mk-stracon.com<\/a>) has 15+ years industry experience in the field of personalized medicine \u2013 from biomarker validation, companion diagnostics development to implementation of such products in the market.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Mikael_Kubista_TATAA_Photo_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Mikael_Kubista_TATAA_Photo_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Mikael_Kubista_TATAA_Photo_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Mikael_Kubista_TATAA_Photo_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Mikael_Kubista_TATAA_Photo_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Mikael_Kubista_TATAA_Photo_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Mikael_Kubista_TATAA_Photo_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33954″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/mikael-kubista\/mikael_kubista_tataa_photo_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Mikael_Kubista_TATAA_Photo_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"1552470840","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Mikael_Kubista_TATAA_Photo_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Mikael_Kubista_TATAA_Photo_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Mikael_Kubista_TATAA_Photo_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMikael Kubista\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
CEO at TATAA Biocenter<\/h5>\n

\n\t\t\t\n\tTwo-Tailed PCR for Precision Diagnostic\n\t\t\t<\/a>\n\t<\/h3>\n\t

In 1996 Kubista invented the light-up probes, which led to the foundation of LightUp Technologies AB as Europe\u00b4s first company focusing on qPCR based diagnostics. He co-founded MultiD Analyses AB, which develops the market leading software GenEx for molecular analysis, and in 2001 Kubista set up TATAA Biocenter as the first laboratory in Europe to obtain flexible ISO 17025 accreditation.<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1.png 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1-201×300.png 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1-686×1024.png 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1-768×1146.png 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1-630×940.png 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1-420×627.png 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1-315×470.png 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33970″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/miroslaw-kornek\/miroslaw_kornek_university_bonn_liquid_biopsy_2020_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1.png” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"0"}” data-image-title=”Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1-201×300.png” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Miroslaw_Kornek_University_Bonn_Liquid_Biopsy_2020_1-686×1024.png”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tMiroslaw Kornek\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Principal Investigator (PI) at The University of Bonn.<\/h5>\n

\n\t\t\t\n\tEVs in hepatobiliary cancer, an evolving story\n\t\t\t<\/a>\n\t<\/h3>\n\t

Dr. Miroslaw Kornek is working as a principal investigator at the Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Germany. He completed his Ph.D. in Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Germany. His position and research work was funded by the German Cancer Foundation (Deutsche Krebshilfe e.V.) and recently by the Deutschen Forschungsgemeinschaft (DFG, German Research Foundation).<\/p>\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"” data-srcset=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1.jpg 820w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1-201×300.jpg 201w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1-686×1024.jpg 686w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1-768×1146.jpg 768w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1-630×940.jpg 630w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1-420×627.jpg 420w, https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1-315×470.jpg 315w” sizes=”(max-width: 820px) 100vw, 820px” data-attachment-id=”33942″ data-permalink=”https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/selina-gaertner\/selina-gaertner_htg-molecular_liquid_biopsy_2020_1\/” data-orig-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1.jpg” data-orig-size=”820,1224″ data-comments-opened=”1″ data-image-meta=”{"aperture":"0","credit":"","camera":"","caption":"","created_timestamp":"0","copyright":"","focal_length":"0","iso":"0","shutter_speed":"0","title":"","orientation":"1"}” data-image-title=”Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1″ data-image-description=”” data-medium-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1-201×300.jpg” data-large-file=”https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/08\/Selina-Gaertner_HTG-Molecular_Liquid_Biopsy_2020_1-686×1024.jpg”>\t\t\t\t\t\t\t<\/a>\n\t\t

\n\t\t\t\t\t\t\t\n\t\t\t\t\t\t\tSelina Gaertner\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/h4>\n\t\t\t\t\t
Medical Affairs Manager EMEA at HTG Molecular Diagnostics<\/h5>\n

\n\t\t\t\n\tQuantitative miRNA Profiling\n\t\t\t<\/a>\n\t<\/h3>\n\t

Selina Gaertner is holding a MSc in Biochemistry and joined HTG Molecular in 2016, where she is living the mission to empower precision medicine at the local level, by bridging Molecular Profiling, Biomarker Signature Development and Molecular Diagnostics. She is focusing on advancing the field of Liquid Biopsy, Early Disease Detection, Companion Diagnostics and Precision Medicine with the Extraction-Free RNA analysis solution HTG EdgeSeq.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Our Speakers (A-Z) Anders St\u00e5hlberg Principal investigator at University of Gothenburg \/ Sahlgrenska University Hospital Technical and biological challenges when analyzing cell-free tumor DNA Anders St\u00e5hlberg is working as principal investigator at the Sahlgrenska Cancer Center, University of Gothenburg and Sahlgrenska University Hospital in Sweden. He has a PhD in molecular biotechnology and has two…<\/p>\n","protected":false},"author":1,"featured_media":31667,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-33918","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nLiquid Biopsy 2020 Speakers • BioTech Pharma Summit<\/title>\n<meta name=\"description\" content=\"On 20 & 21 February 2020, Lisbon (Portugal) will host the BioTech Pharma Summit: Liquid Biopsy 2020 conference. This year\u2019s event will bring together the leaders in the field from pharma, biotech, Dx companies and healthcare and be the home of multi-stakeholder and pan-industry collaboration for liquid biopsy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Liquid Biopsy 2020 Speakers • BioTech Pharma Summit\" \/>\n<meta property=\"og:description\" content=\"On 20 & 21 February 2020, Lisbon (Portugal) will host the BioTech Pharma Summit: Liquid Biopsy 2020 conference. This year\u2019s event will bring together the leaders in the field from pharma, biotech, Dx companies and healthcare and be the home of multi-stakeholder and pan-industry collaboration for liquid biopsy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/\" \/>\n<meta property=\"og:site_name\" content=\"BioTech Pharma Summit\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/biotechpharmasummit\/\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-19T10:30:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Liquid_Biopsy_Lisbon_February_2020.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1940\" \/>\n\t<meta property=\"og:image:height\" content=\"1013\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@biotechsummit\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/\",\"name\":\"Liquid Biopsy 2020 Speakers • BioTech Pharma Summit\",\"isPartOf\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Liquid_Biopsy_Lisbon_February_2020.png\",\"datePublished\":\"2020-08-28T14:54:30+00:00\",\"dateModified\":\"2021-03-19T10:30:13+00:00\",\"description\":\"On 20 & 21 February 2020, Lisbon (Portugal) will host the BioTech Pharma Summit: Liquid Biopsy 2020 conference. This year\u2019s event will bring together the leaders in the field from pharma, biotech, Dx companies and healthcare and be the home of multi-stakeholder and pan-industry collaboration for liquid biopsy\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/#primaryimage\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Liquid_Biopsy_Lisbon_February_2020.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Liquid_Biopsy_Lisbon_February_2020.png\",\"width\":1940,\"height\":1013},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.biotechpharmasummit.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Liquid Biopsy 2020 Speakers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#website\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"name\":\"BioTech Pharma Summit\",\"description\":\"The Tomorrow's healthcare congress\",\"publisher\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#organization\",\"name\":\"EPM Group\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"contentUrl\":\"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png\",\"width\":2000,\"height\":2000,\"caption\":\"EPM Group\"},\"image\":{\"@id\":\"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/biotechpharmasummit\/\",\"https:\/\/x.com\/biotechsummit\",\"https:\/\/www.instagram.com\/biotechpharmasummit\/\",\"https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Liquid Biopsy 2020 Speakers • BioTech Pharma Summit","description":"On 20 & 21 February 2020, Lisbon (Portugal) will host the BioTech Pharma Summit: Liquid Biopsy 2020 conference. This year\u2019s event will bring together the leaders in the field from pharma, biotech, Dx companies and healthcare and be the home of multi-stakeholder and pan-industry collaboration for liquid biopsy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/","og_locale":"en_US","og_type":"article","og_title":"Liquid Biopsy 2020 Speakers • BioTech Pharma Summit","og_description":"On 20 & 21 February 2020, Lisbon (Portugal) will host the BioTech Pharma Summit: Liquid Biopsy 2020 conference. This year\u2019s event will bring together the leaders in the field from pharma, biotech, Dx companies and healthcare and be the home of multi-stakeholder and pan-industry collaboration for liquid biopsy","og_url":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/","og_site_name":"BioTech Pharma Summit","article_publisher":"https:\/\/www.facebook.com\/biotechpharmasummit\/","article_modified_time":"2021-03-19T10:30:13+00:00","og_image":[{"width":1940,"height":1013,"url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Liquid_Biopsy_Lisbon_February_2020.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@biotechsummit","twitter_misc":{"Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/","url":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/","name":"Liquid Biopsy 2020 Speakers • BioTech Pharma Summit","isPartOf":{"@id":"https:\/\/www.biotechpharmasummit.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/#primaryimage"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/#primaryimage"},"thumbnailUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Liquid_Biopsy_Lisbon_February_2020.png","datePublished":"2020-08-28T14:54:30+00:00","dateModified":"2021-03-19T10:30:13+00:00","description":"On 20 & 21 February 2020, Lisbon (Portugal) will host the BioTech Pharma Summit: Liquid Biopsy 2020 conference. This year\u2019s event will bring together the leaders in the field from pharma, biotech, Dx companies and healthcare and be the home of multi-stakeholder and pan-industry collaboration for liquid biopsy","breadcrumb":{"@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/#primaryimage","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Liquid_Biopsy_Lisbon_February_2020.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/06\/Banner_Liquid_Biopsy_Lisbon_February_2020.png","width":1940,"height":1013},{"@type":"BreadcrumbList","@id":"https:\/\/www.biotechpharmasummit.com\/index.php\/liquid-biopsy-2020-speakers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.biotechpharmasummit.com\/"},{"@type":"ListItem","position":2,"name":"Liquid Biopsy 2020 Speakers"}]},{"@type":"WebSite","@id":"https:\/\/www.biotechpharmasummit.com\/#website","url":"https:\/\/www.biotechpharmasummit.com\/","name":"BioTech Pharma Summit","description":"The Tomorrow's healthcare congress","publisher":{"@id":"https:\/\/www.biotechpharmasummit.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biotechpharmasummit.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.biotechpharmasummit.com\/#organization","name":"EPM Group","url":"https:\/\/www.biotechpharmasummit.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","contentUrl":"https:\/\/www.biotechpharmasummit.com\/wp-content\/uploads\/2020\/05\/B_2_Logo_BioTech_Pharma_Summit_Porto.png","width":2000,"height":2000,"caption":"EPM Group"},"image":{"@id":"https:\/\/www.biotechpharmasummit.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/biotechpharmasummit\/","https:\/\/x.com\/biotechsummit","https:\/\/www.instagram.com\/biotechpharmasummit\/","https:\/\/www.linkedin.com\/company\/biotech-pharma-summit\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/comments?post=33918"}],"version-history":[{"count":4,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33918\/revisions"}],"predecessor-version":[{"id":36188,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/pages\/33918\/revisions\/36188"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media\/31667"}],"wp:attachment":[{"href":"https:\/\/www.biotechpharmasummit.com\/index.php\/wp-json\/wp\/v2\/media?parent=33918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}